STATEMENT OF CONCERN
Marijuana Policy in Massachusetts

From: Pediatricians, Mental Health and Addiction Clinicians & Scientists of Massachusetts

May 2019

David Beckmann, MD, MPH
Child and Adolescent Psychiatrist, Addiction Recovery Management Service (ARMS), Massachusetts General Hospital • Instructor of Psychiatry, Harvard Medical School

Suzanne Bender, MD
Co-Director Pediatric GI Psychiatry, Massachusetts General Hospital • Assistant professor in Psychiatry, Part-Time, Harvard Medical School

Linden J. Cassidy, MD
Psychiatrist in Child & Adolescent Psychiatry, Massachusetts General Hospital

Corinne Cather, PhD
Director, Center of Excellence in Psychosocial and Systemic Research; Director, Psychological Services of the MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital • Associate Professor of Psychology, Harvard Medical School

Nicholas Chadi, MD
Pediatrician Specialized in Adolescent and Addiction Medicine, Adolescent Substance Use and Addiction Program, Boston Children’s Hospital • Pediatric Addiction Medicine Fellow, Harvard Medical School

Margaret Chang, MD, FAAP
Pediatrics and Internal Medicine, Tri-River Family Health Center, Uxbridge, MA

Sandra DeJong, MD
Assistant Professor in Psychiatry, Harvard Medical School

A. Eden Evins, MD, MPH
Founding Director, Massachusetts General Hospital Center for Addiction Medicine • Cox Family Professor of Psychiatry in the Field of Addiction Medicine, Harvard Medical School

Xiaoduo Fan, MD, MPH, MSc
Associate Professor of Psychiatry; Director, Psychotic Disorders Program; Director, China Mental Health Program, UMass Memorial Health Care/UMass Medical School

Deb Greene MD, FACEP
Associate Chair, Emerson Hospital Emergency Department

Jodi Gilman, PhD
Associate Professor, Harvard Medical School • Director of Neuroscience, Center for Addiction Medicine, Massachusetts General Hospital

Marguerite Gump, MD
Valley Medical Group, Greenfield, MA

Scott Hadland, MD, MPH, MS
Assistant Professor of Pediatrics, Boston University School of Medicine • Director, Urban Health and Advocacy Track, Boston Children's Hospital and Boston Medical Center • Associate Program Director, Boston Combined Residency Program in Pediatrics, Boston Medical Center

Sion Harris, PhD, CPH
Associate Professor of Pediatrics, Harvard Medical School • Director, Center for Adolescent Substance Use and Addiction Research (CeASAR), Boston Children’s Hospital

Daphne J. Holt, MD, PhD
Co-Director, Schizophrenia Clinical and Research Program, Massachusetts General Hospital • Director, Emotion and Social Neuroscience Laboratory, Massachusetts General Hospital • Associate Professor of Psychiatry, Harvard Medical School

Jeffrey Hopkins, MD, FACEP
Chair, Department of Emergency Medicine, Milford Regional Medical Center • Assistant Professor, UMass Medical School • Past President, Massachusetts College of Emergency Physicians
Tia Horner, MD
Staff Child & Adolescent Psychiatrist, Home Base Program, Massachusetts General Hospital

Nandana Kansra MD, MPH
Assistant Professor, Department of Medicine, UMass Medical School • Physician, Saint Vincent Medical Group at Shrewsbury

Rachel Katz, FNP
Valley Medical Group, Greenfield, MA

John F. Kelly, PhD, ABPP
Elizabeth R. Spallin Associate Professor of Psychiatry, Harvard Medical School • Director, MGH Recovery Research Institute; Program Director, MGH Addiction Recovery Management Service (ARMS); Associate Director, MGH Center for Addiction Medicine

Deborah L. Levy, PhD
Director, Psychology Research Laboratory, McLean Hospital • Associate Professor of Psychology, Department of Psychiatry, Harvard Medical School

Sharon Levy, MD, MPH
Director, Adolescent Substance Use and Addiction Program, Boston Children’s Hospital • Associate Professor of Pediatrics, Harvard Medical School

Jeffrey C. Lukas, MD
Assistant Professor of Pediatrics, UMass Medical School Pediatrics Director, Tri-River Family Health Center

Bertha K. Madras, PhD
Director, Laboratory of Addiction Neurobiology, McLean Hospital • Professor of Psychobiology, Department of Psychiatry, Harvard Medical School

James Mckown, PhD
Clinical Director, Addiction Recovery Management Service (ARMS), Massachusetts General Hospital

Safdar Medina, MD, FAAP
Assistant Professor of Pediatrics, UMass Medical School Pediatrician, Tri-River Family Health Center

National Alliance on Mental Illness of Massachusetts

Cambridge-Middlesex Board of Directors. National Alliance on Mental Illness (NAMI)

Ruth A. Potee, MD
Family Physician and Addiction Medicine Physician, Valley Medical Group in Greenfield, MA • Medical Director for the Franklin County House of Corrections • Medical Director for the Franklin Recovery and Treatment Center • Medical Director for the Pioneer Valley Regional School District • Chair of the Healthcare Solutions of the Opioid Taskforce of Franklin County

Lisa F. Price, MD
Assistant Director, School Psychiatry Program, Massachusetts General Hospital • Instructor, Harvard Medical School

Anthony J. Rothschild, M.D.
Irving S. and Betty Brudnick Endowed Chair and Professor of Psychiatry; Vice-Chair for Research, Department of Psychiatry; Director, Center for Psychopharmacologic Research and Treatment; Chair, Psychiatry Grand Rounds Committee, UMass Medical School Department of Psychiatry

Dana Sarvey, MD
Associate Medical Director, McLean Adolescent Acute Residential Treatment Program • Instructor in Psychiatry, Harvard Medical School

Randi Melissa Schuster, PhD
Assistant Professor, Harvard Medical School • Director of Neuropsychology, Center for Addiction Medicine, Massachusetts General Hospital

Derri Shtasel, MD, MPH
Michele and Howard J Kessler Chair and Director, Division of Public and Community Psychiatry, Massachusetts General Hospital • Associate Professor of Psychiatry, Harvard Medical School

Sherri Snyder-Roche, MA, LMHC
Private Practice, Integrated Psychotherapy

Amy KJ Turncliff, PhD
Chief Scientific Advisor, Massachusetts Prevention Alliance

Corrie Vilsaint, PhD
Research Fellow in Psychology, Recovery Research Institute, Center for Addiction Medicine, Department of Psychiatry Massachusetts General Hospital & Harvard Medical School

Mark Vining, MD
Associate Professor of Pediatrics, Program Director, Pediatrics Residency, UMass Medical School • Director, Newborn Nursery, UMass Memorial Health Care

Amy Yule, MD
Medical Director, Addiction Recovery Management Service (ARMS), Massachusetts General Hospital • Instructor, Harvard Medical School

Cynthia Berkowitz, MD

Mary Jeffers-Terry, RNPC

Karen Peterson, MD

Michelle Dalal, MD
WHO ARE WE?

We represent major medical centers, medical schools, and health-related organizations in Massachusetts. We are clinicians, researchers, scientists, and other public health professionals.

STATEMENT OF CONCERN

We disagree with how marijuana policy is being shaped in the Commonwealth. Marijuana* is being governed and regulated as if it were an “ordinary commodity”, rather than following a Public Health Framework (See Table 1).

- The science is clear; marijuana, specifically the psychoactive chemical THC (delta-9-tetrahydrocannabinol), has the potential to do significant harm to public health.
- There is a lack of public awareness about these potential dangers.
- Given that the tobacco industry has spent $billions to partner with JUUL and a marijuana company, we expect a significant increase in the use of high THC vapes.
- Diversion of high THC products (≥10%), vapes and edibles, to MA youth is a growing concern.
- Regulatory failure in the case of the marijuana industry, like tobacco, opioids and vape devices, is likely unless there is a prioritized focus on public health.
- When public health is not prioritized in the regulation of addictive substances, the public and our young people are put at risk.

We provide fully cited supplementary material with this statement.

SUMMARY OF KEY NEGATIVE EFFECTS OF THC

- Risk of addiction;
- Impairment of cognitive (intellectual) function; and
- Increased risk of serious mental health problems including acute psychosis (e.g., hallucinations, delusions), paranoia, schizophrenia, depression, anxiety, and suicide, with growing scientific evidence that daily use of high THC products bring greater risk.
- We are seeing these negative health effects in our patient populations.
- Just as not all tobacco use causes cancer, not all marijuana/THC use causes the negative effects listed above; however, the risk is substantial enough to require policies which discourage use.

* NOTE: We use the term “marijuana” rather than “cannabis” throughout, because “marijuana” is used in MGL 94G.
COLLECTIVELY, RECENT SCIENTIFIC FINDINGS INDICATE

A growing number of people are using marijuana/THC daily or near daily, with higher levels of use among those in low income groups.\textsuperscript{3,4,5}

50% of first-episode psychosis cases in Amsterdam may be attributable to the use of high THC (≥10%) marijuana, meaning that they are preventable.\textsuperscript{6}

41% of those who experience cannabis-induced psychosis later convert to schizophrenia.\textsuperscript{7}

REQUEST FOR ACTION

Regulate and govern the commercial marijuana market, in Massachusetts, using a \textbf{Public Health Framework} (See Table 1 on page 3).\textsuperscript{1}

This regulatory framework prioritizes population-level health over commercial market interests and supports the maximum benefit for the largest number of people, including those most vulnerable.
# TABLE 1: A PUBLIC HEALTH FRAMEWORK for Legalized Retail Marijuana Based on the US Experience: Avoiding a New Tobacco Industry¹ (Adapted from Barry & Glantz, 2016).

<table>
<thead>
<tr>
<th>Lead Agency</th>
<th>Department of Health</th>
<th>✔</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advisory Committees</td>
<td>Membership solely of public health experts</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>No decision-making authority of marijuana industry or vested interests</td>
<td>✔</td>
</tr>
<tr>
<td>Regulatory Complexity</td>
<td>Creates a single system of retail marijuana</td>
<td>✔</td>
</tr>
<tr>
<td>Tax Revenue</td>
<td>Tax covers full costs</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Dedicated revenue to marijuana prevention, control, and research</td>
<td>✔</td>
</tr>
<tr>
<td>Prevention and Control Programs</td>
<td>Media Campaign aimed at general population (not just youth)</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Media Campaign modeled on social norm change</td>
<td>✔</td>
</tr>
<tr>
<td>Smokefree Laws</td>
<td>Prohibit any public use of marijuana</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit marijuana use wherever tobacco smoking is prohibited</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Protect local control</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit indoor use in marijuana retail stores or marijuana clubs</td>
<td>✔</td>
</tr>
<tr>
<td>Marketing and Advertising</td>
<td>Prohibit free or discounted samples</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit cartoon characters</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit sport and cultural event sponsorship</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit product placement in popular media and cobranded merchandise</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit therapeutic claims</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit outdoor advertising on billboards</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit advertising on television and radio</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Restrict advertising in print and digital communications with 15% threshold</td>
<td>✔</td>
</tr>
<tr>
<td>Licensing Rules</td>
<td>Impose serious penalties on retailers’ underage sales</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit sale of tobacco or alcohol in marijuana retail stores</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit tobacco and alcohol retailers from holding marijuana license</td>
<td>✔</td>
</tr>
<tr>
<td>Retail Sales</td>
<td>Require retailer use age verification system (ID scanners) at point of sale</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit retailers within 1,000 feet of underage-sensitive areas</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit electronic commerce (internet, mail order, texts, social media)</td>
<td>✔</td>
</tr>
<tr>
<td>Product Standards</td>
<td>Require strong potency limits and product quality testing</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibit products containing additives (nicotine, alcohol, caffeine, or toxic chemicals)</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Prohibits flavored products appealing to underage persons</td>
<td>✔</td>
</tr>
<tr>
<td>Warning Labels</td>
<td>Require warning labels modeled on state-of-the-art tobacco labels</td>
<td>✔</td>
</tr>
</tbody>
</table>
SUMMARY OF CONCERNS BASED ON CURRENT SCIENCE
Marijuana Policy Impacts the Health and Safety of Our Communities and Our Children

- Marijuana can be addictive. The earlier someone begins using marijuana, the higher their risk of addiction – older studies with low THC marijuana, showed that one in six users (17%) who start under age 18 become dependent; 25-50% of teen heavy users become addicted. Newer studies indicate nearly 3 of 10 users manifested a use disorder in 2012–2013. Among youth receiving substance use disorder treatment in publicly funded programs, marijuana accounts for the largest percentage of admissions—about 76% among those 12 to 17 years old. 3,8-14

THC (the psychoactive component of marijuana) activates the reward system in a similar way to other addictive drugs such as alcohol, opiates and cocaine, resulting in the release of the chemical dopamine and risk of addiction. The endocannabinoid system is important in many physiological processes, including proper connections between brain regions. Use of marijuana/THC during adolescence and young adulthood may disrupt brain development.

- Marijuana today contains more THC, making it more harmful. Highly concentrated marijuana/THC products available today can be more than 90% THC. High potency marijuana with dramatic increases in THC:CBD ratios, often in the form of candies, cookies, sodas, and hashish concentrates (e.g., budder, wax, honey oil, shatter), that can be “vaped”, suggest that commercial marijuana is becoming an increasingly harmful product that is more likely to cause addiction and negative health consequences in adolescents and young adults.15-19

25% to 50% of teen heavy marijuana users become addicted

76% of teen substance abuse treatment admissions are for marijuana

more than 90% THC potency in some marijuana products
Use of marijuana/THC is associated with long-term negative consequences, particularly for adolescents and young adults <25 years old.

- Impaired cognitive and intellectual development: Marijuana use by adolescents can impair brain development (with negative effects on focus and motivation, etc.), reduce academic success, impact long-term career growth, and even lower IQ.20-25

- Increased risk of serious mental illness:
  - It is well documented that THC use can induce psychosis-like symptoms (e.g., cannabis-induced psychosis). More recent research shows that frequent use and/or high doses of THC are more likely to bring on first-episode psychosis (thinking that is detached from reality, sometimes including hallucinations), with increased risk of 2-5x (200-500%).2,6,7,26-30
  - Marijuana use increases the risk of developing serious psychotic disorders including schizophrenia and bipolar disorder; this conversion occurs for nearly 50% of those diagnosed with cannabis-induced psychosis. This is especially true for those who start using during adolescence, are heavy users of high THC products, and those at higher genetic risk for these disorders, but also possibly among those with no family history.7,27,31-36
  - Regular marijuana use has been linked to increased risk for several other mental health problems, including depression, anxiety, suicidal thoughts, and personality disturbances. Additionally, studies show that high THC products may worsen PTSD and increase the risk of violence in the long-term.21,37-40

- Marijuana use during pregnancy may result in altered brain development in childhood. Research suggests that marijuana use during pregnancy may be linked to subtle neurological changes and, later in childhood, to reduced problem-solving skills, memory, and attention.41
Statement of Concern—Marijuana Policy in Massachusetts

CURRENT MARIJUANA REGULATION IS COUNTERPRODUCTIVE TO HEALTH EQUITY GOALS

Public health and addiction prevention professionals have been closely watching the development and roll-out of regulations for a recreational marijuana industry in Massachusetts. Serious concerns continue to heighten about the increased availability of highly potent THC products whose marketing has broad appeal to youth and young adults. The health concerns of marijuana use are particularly acute for vulnerable and marginalized populations, including adolescents and young adults <25, LGBTQ persons, those with mental health problems and those of low socioeconomic position. Of particular concern is the “Social Equity Program” included in the Cannabis Control Commission's regulations.

The Social Equity Program written into the regulations increases availability and access to marijuana among the populations already disproportionately affected by cannabis use disorder and youth marijuana use, including people of color. The “Social Equity Program” is well intentioned: It aims to distribute the “economic success” of a regulated marijuana market among communities that have traditionally been excluded from economic opportunity. However, marijuana is not an ordinary commodity; low income and minority communities have a perilous history of being targeted by predatory industries that profit from those who become addicted. For example, tobacco manufacturers have exploited low income communities with deep price discounting, targeted advertising and high density of retail outlets, often near schools. These targeted efforts not only increase access and opportunity for young people to use, but also shape social norms and increase the social acceptability of use.

The multi-billion dollar investment made by Altria, the parent company of the tobacco giant Philip Morris, in JUUL and the marijuana company Cronos heightens significant concerns. Further, PAX Labs, the parent company from which JUUL spun out of, announced in April 2019 that they had successfully raised $420M; PAX makes JUUL-like vaporizers specifically for marijuana dry leaf, high THC oils and concentrates.

“By targeting low income communities for marijuana retail outlets, the Social Equity Program is likely to increase health inequities and disparities among marginalized populations.”
By targeting low income communities for marijuana retail outlets, the Social Equity Program is likely to increase health inequities and disparities among marginalized populations. The Cannabis Control Commission’s regulatory language prioritizes market growth, targets communities with high unemployment rates (low income) and is directly counter-productive to the state's health equity, behavioral health and addiction prevention goals. Some recognize this; for example:

- In 2018, the Los Angeles Times wrote “After decades of black Americans being cast as the face of the underground pot market, Compton and other Southern California cities with large African American populations have opted against legalizing the pot trade, worried about the effects on the community and the message it sends.” 55

- In 2019, a NYT article on cannabis legislation stated “…Among the most vocal opponents were a handful of African-American Democratic lawmakers who split with their party over legalization, arguing that it would be a public health menace to their communities.” 56

- In 2019, a Boston Globe article wrote “…there are many in minority neighborhoods who don’t care which racial groups prevail in the marketplace of marijuana …Among them are local pastors [including Rev. Zenetta Armstrong of Mattapan], medical clinicians, and parents who insist their struggling neighborhoods, of all places, shouldn’t have to deal with marijuana’s potentially damaging effects.” 57

- Others to voice serious concerns regarding marijuana commercialization include the Illinois NAACP and Will Jones III of the organization Two is Enough (TIE DC). 58-60

To support substance use prevention and social, emotional, and mental health promotion, state and local leaders must support strategies that minimize the reach of the marijuana industry and promote healthy, drug-free norms for families and communities.

“To support substance use prevention and social, emotional, and mental health promotion, state and local leaders must support strategies that minimize the reach of the marijuana industry and promote healthy, drug-free norms for families and communities.”
1. Protect Vulnerable Populations

- Temporarily suspend licensing and conduct a Public Health Impact Assessment, by public health professionals, of the Social Equity Program with all the associated components to avoid worsening health inequities and disparities among vulnerable populations and communities.

2. Implement Product Standards and Safety

- Establish strict potency limits and regulation of THC:CBD ratio (e.g., Switzerland, Netherlands, and Uruguay).
- No sale of products that are especially appealing to children and adolescents.
- Model warning labels after best practices in “tobacco” warning labels (e.g., cover 70% of packaging, rotate warnings so all are exposed to consumers, etc.)
- Label information should include that “It is illegal to give marijuana/THC products to anyone under 21” and should be on all packaging.
- Warnings need to include “increased risk of serious mental illness including psychosis, paranoia, suicidal thoughts, and depression”. Those who use need to be warned that “if they have hallucinations, delusions, or other psychotic-like experiences while intoxicated, it is an indicator that they may develop a serious psychotic illness with continued use.”
- Warnings issued, and required, by Canada are a model: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/regulations-support-cannabis-act/health-warning-messages.html

3. Educate the Public to Discourage Use

- Develop an education campaign that warns of the real risks of marijuana use, including mental illness.
- Provide funding for public messaging to prevent underage use and OUI Marijuana.

4. Evaluate and Track Negative Impacts

- To avoid the harms of “a medical system only in name,” the medical marijuana program should either be regulated like medicine or combined with the recreational market.
- Ensure a comprehensive data monitoring plan. The baseline study was sorely inadequate, and the data tracking plan is not comprehensive or transparent. For example: the Cannabis Control Commission is not adequately monitoring underage use.
- Peer review is needed for the Cannabis Control Commission’s research program.
5. Avoid Regulatory Capture and Failure

- Massachusetts is failing to meet many of the public health standards for regulation of marijuana using a Public Health Framework (Table 1), making regulatory failure likely.

- Stronger and clearer conflict of interest standards for the Cannabis Control Commission. The goal of this Commission should be to regulate the marijuana industry in a way that discourages use, minimizes harm, and prioritizes public health and safety.

- Strict limits on industry reach and lobbying based on lessons-learned from the Tobacco Industry Master Settlement Agreement (Section III):
  - No participating manufacturer may oppose, or cause to be opposed, legislative proposals or administrative rules intended by their terms to reduce Youth access to, and the incidence of Youth consumption of, marijuana products.
  - Prohibit practices that seek to hide negative information about marijuana/THC, such as: Lobbying against measures aimed to prevent underage use; lobbying against labeling that lists health harms; lobbying against measures that seek to reduce heavy consumption of marijuana that may lead to psychosis or other mental health disorders; agreements to suppress health-related research; material misrepresentations about health consequences of using marijuana-related products.

- No Advisory Committee, including the Impaired Driving Committee, should include industry representation.

6. Reduce Underage Use Through Best Practices

- Indefinitely delay the licensing of social consumption establishments (primary and mixed use) and licensing of home delivery of marijuana products.

- No advertising by ancillary marijuana businesses (e.g., Weedmaps) and no advertisement/marketing by marijuana businesses in any public media outlet.

- Marketing and advertising should be limited to an over-21 only audience where 100% of the audience is over 21, based on ID verification.

- Increase age of entry for local marijuana-related events to 21, consistent with the Marijuana laws for sales and use.

- Include clear regulatory language that expands the buffer zones and that the distance be measured from the property line not the physical building structure, between places where children congregate and marijuana businesses. The clear language should include "public and private schools, daycare center, any facility or location in which children commonly congregate (e.g., public library, playground or park)". Municipalities should not be allowed to reduce the buffer zone below 500 ft.

- Prohibit internet sales of marijuana/THC products.

- Transaction limits and tracking: Limits on the mg of THC and the frequency of consumer purchases are necessary. The regulations limit each package to 20 x 5mg servings but do not indicate how many sales are permissible per day, week, month. This increases the risk of diversion to those under age. For concentrate, 5g of 90% THC may be equivalent to 4,500mg THC. This lack of oversight increases the opportunity for diversion to those under 21.
REFERENCES


REFERENCES CONTINUED


60. Word: The Truth to Marijuana Legalization/Commercialization. Will Jones III. https://www.youtube.com/watch?v=G3i1k619PgY
